挪威处方药物使用与后续帕金森病风险的关联:一项全药物关联研究
该研究基于挪威全国2004至2019年登记数据,纳入3,223,672人,其中15,849人随访期间发生帕金森病,筛选出31个与帕金森病风险相关的药物类别。肾素-血管紧张素系统药物、全身用糖皮质激素和疫苗与帕金森病风险降低相关,而治疗便秘、泌尿系统问题和抑郁的药物与风险升高相关。
要点
- 肾素-血管紧张素系统药物、全身用糖皮质激素和疫苗与帕金森病风险降低相关。
- 治疗便秘、泌尿系统问题和抑郁的药物与后续帕金森病诊断风险升高相关。
- 利用药物流行病学监测药物使用可能有助于识别前驱期帕金森病个体。
核心结论
- 该全药物关联研究识别出31个与帕金森病风险变化相关的药物类别,揭示肾素-血管紧张素系统药物、疫苗和糖皮质激素与帕金森病风险的关联,并提示利用药物流行病学监测药物使用可能有助于识别前驱期帕金森病个体。
研究设计与样本
- 基于登记数据的队列研究,使用2004年至2019年挪威全国人口数据,链接挪威处方登记库,包含超过6亿条个体处方记录。
- 药物类别按解剖治疗化学(ATC)代码第2级(治疗亚组)筛选,采用Cox回归模型估计风险比(HR)和95%CI,所有P值使用错误发现率校正多重检验,并进行暴露定义、时间滞后和剂量反应的敏感性分析。
主要发现
- 研究人群共3,223,672人,其中15,849人在随访期间发生帕金森病。
- 共识别出31个与帕金森病风险在挪威随访期间有统计学显著关联的药物类别。
- 肾素-血管紧张素系统药物与帕金森病风险降低相关(HR 0.92,95%CI 0.89-0.95),全身用糖皮质激素(HR 0.88,95%CI 0.84-0.93)和疫苗(HR 0.89,95%CI 0.82-0.96)同样与风险降低相关,且关联可持续至帕金森病发病前10年。
- 治疗便秘、泌尿系统问题和抑郁等帕金森病前驱症状相关疾病的药物类别与后续帕金森病诊断风险升高相关,HR分别为1.6(95%CI 1.49-1.73)、1.48(95%CI 1.42-1.53)和1.94(95%CI 1.87-2.01)。
关键数值与推荐
- 肾素-血管紧张素系统药物:HR 0.92(95%CI 0.89-0.95),与帕金森病风险降低相关。
- 全身用糖皮质激素:HR 0.88(95%CI 0.84-0.93),与帕金森病风险降低相关。
- 疫苗:HR 0.89(95%CI 0.82-0.96),与帕金森病风险降低相关。
- 便秘治疗药物:HR 1.6(95%CI 1.49-1.73),与帕金森病风险升高相关。
- 泌尿系统问题治疗药物:HR 1.48(95%CI 1.42-1.53),与帕金森病风险升高相关;抑郁治疗药物:HR 1.94(95%CI 1.87-2.01),与帕金森病风险升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The incidence rate of Parkinson disease (PD) has been increasing rapidly during the past years. Yet, no treatments exist to prevent or slow the progression of the disease. Moreover, we are unable to detect early disease stages during which intervention with disease-modifying therapies is most likely to succeed. The objective of this study was to perform an agnostic drug-wide association study estimating the association between the use of any of the drugs prescribed in Norway and the subsequent risk of PD. METHODS: This registry-based cohort study use data from the entire Norwegian population between 2004 and 2019 linked to the Norwegian Prescription Registry, with more than 600 million individual prescriptions. Drug classes were screened according to Anatomical Therapeutic Chemical codes at level 2, corresponding to therapeutic subgroups. We used Cox regression models to estimate hazard ratios (HRs) and 95% CIs for the associations between drug classes and PD risk. All p values were corrected for multiple testing using the false discovery rate. In addition, we conducted sensitivity analyses of exposure definition as well as time-lag and dose-response analyses. RESULTS: The study population comprised 3,223,672 individuals, 15,849 of whom developed PD during the follow-up. We identified 31 drug classes that were statistically significantly associated with PD risk in Norway during the follow-up. Drugs acting on the renin-angiotensin system (HR 0.92, 95% CI 0.89-0.95), corticosteroids for systemic use (0.88, 95% CI 0.84-0.93), and vaccines (0.89, 95% CI 0.82-0.96) were associated with a decreased risk of PD even up to 10 years before PD onset. Drug classes used to treat symptoms related to prodromal signs of PD, such as constipation, urological issues, and depression, were associated with an increased risk of subsequent diagnosis of PD with HRs of 1.6 (95% CI 1.49-1.73), 1.48 (1.42-1.53), and 1.94 (1.87-2.01), respectively. DISCUSSION: This drug-wide study identified 31 drug classes that were associated with the PD risk change. It reveals the links of renin-angiotensin system medications, vaccines, and corticosteroids with PD risk and suggests that monitoring drug usage using pharmacoepidemiology may allow identifying individuals with prodromal PD.
引用
- Romanowska J, Bjornevik K, Cortese M, et al. Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study. Neurology. 2023. PMID: 37816645. doi:10.1212/WNL.0000000000207899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。